Adaptive randomization of neratinib in early breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Quinolines

abstract

  • Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer. (Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).

authors

publication date

  • July 7, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5259558

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1513750

PubMed ID

  • 27406346

Additional Document Info

start page

  • 11

end page

  • 22

volume

  • 375

number

  • 1